The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
ADEL Enters $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, an Alzheimer's Disease Therapy
Dec 15, 2025•6 months ago
Contract Type
agreement
South KoreaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
ADEL, Inc. has signed an exclusive worldwide license agreement with Sanofi for ADEL-Y01, a promising therapy for Alzheimer's disease. The agreement potentially values up to $1.04 billion, including an upfront payment of $80 million and additional milestone payments.
Company Information
Company
ADEL
Location
South Korea
About
ADEL, Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases like Alzheimer's Disease. The company is dedicated to innovative research and development, particularly in the field of monoclonal antibodies. ADEL utilizes a proprietary platform to advance its drug candidates through discovery and clinical trials.
South KoreaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma